SciBase, a Swedish firm, won FDA approval to introduce its Nevisense system to help dermatologists assess suspect cutaneous lesions that may be melanoma tumors. Unlike many technologies that have been attempted to characterize cancerous lesions, this one uses electrical impedance rather than optical methods.
The system delivers electric current at (Read more...)